Compare NSP & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | PHAT |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.5M | 894.0M |
| IPO Year | 1996 | 2019 |
| Metric | NSP | PHAT |
|---|---|---|
| Price | $26.50 | $10.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $47.67 | $19.50 |
| AVG Volume (30 Days) | ★ 1.1M | 940.4K |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 8.95% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,812,000,000.00 | $175,110,000.00 |
| Revenue This Year | $3.45 | $92.15 |
| Revenue Next Year | $6.95 | $59.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.51 | ★ 216.93 |
| 52 Week Low | $18.57 | $2.21 |
| 52 Week High | $90.63 | $18.31 |
| Indicator | NSP | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 43.50 |
| Support Level | $18.57 | $10.06 |
| Resistance Level | $48.91 | $12.62 |
| Average True Range (ATR) | 1.72 | 0.67 |
| MACD | 1.15 | 0.08 |
| Stochastic Oscillator | 84.65 | 35.00 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.